IFP Advisors Inc Sells 72 Shares of Zoetis Inc. $ZTS

IFP Advisors Inc lowered its stake in shares of Zoetis Inc. (NYSE:ZTSFree Report) by 0.7% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 9,874 shares of the company’s stock after selling 72 shares during the quarter. IFP Advisors Inc’s holdings in Zoetis were worth $1,540,000 at the end of the most recent quarter.

Several other institutional investors have also bought and sold shares of ZTS. Nova Wealth Management Inc. bought a new stake in Zoetis during the first quarter worth $25,000. 1248 Management LLC purchased a new position in Zoetis in the first quarter worth $27,000. Saudi Central Bank purchased a new position in Zoetis in the first quarter worth $29,000. Cornerstone Planning Group LLC boosted its position in Zoetis by 79.3% in the first quarter. Cornerstone Planning Group LLC now owns 199 shares of the company’s stock worth $30,000 after purchasing an additional 88 shares during the last quarter. Finally, REAP Financial Group LLC boosted its position in Zoetis by 201.5% in the second quarter. REAP Financial Group LLC now owns 196 shares of the company’s stock worth $31,000 after purchasing an additional 131 shares during the last quarter. Institutional investors own 92.80% of the company’s stock.

Zoetis Stock Down 1.6%

Shares of NYSE ZTS opened at $141.05 on Friday. Zoetis Inc. has a one year low of $139.34 and a one year high of $196.55. The company has a debt-to-equity ratio of 1.05, a current ratio of 1.76 and a quick ratio of 1.04. The business’s fifty day moving average price is $149.24 and its 200-day moving average price is $154.41. The stock has a market capitalization of $62.51 billion, a PE ratio of 24.28, a P/E/G ratio of 2.26 and a beta of 0.90.

Zoetis (NYSE:ZTSGet Free Report) last issued its quarterly earnings results on Tuesday, August 5th. The company reported $1.76 EPS for the quarter, beating analysts’ consensus estimates of $1.62 by $0.14. Zoetis had a return on equity of 56.90% and a net margin of 27.83%.The firm had revenue of $2.46 billion for the quarter, compared to analysts’ expectations of $2.41 billion. During the same quarter in the prior year, the firm earned $1.56 EPS. The business’s revenue for the quarter was up 4.2% compared to the same quarter last year. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. On average, equities research analysts anticipate that Zoetis Inc. will post 6.07 EPS for the current year.

Zoetis Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 2nd. Investors of record on Friday, October 31st will be paid a dividend of $0.50 per share. This represents a $2.00 dividend on an annualized basis and a dividend yield of 1.4%. The ex-dividend date is Friday, October 31st. Zoetis’s payout ratio is presently 34.42%.

Wall Street Analysts Forecast Growth

Several research analysts have weighed in on ZTS shares. Leerink Partners cut Zoetis from an “outperform” rating to a “market perform” rating and cut their price objective for the stock from $180.00 to $155.00 in a research report on Thursday, July 17th. Piper Sandler boosted their price objective on Zoetis from $210.00 to $215.00 and gave the stock an “overweight” rating in a research report on Monday, August 11th. Stifel Nicolaus cut Zoetis from a “buy” rating to a “hold” rating and cut their price objective for the stock from $165.00 to $160.00 in a research report on Wednesday, June 18th. Argus reissued a “buy” rating and issued a $190.00 price objective on shares of Zoetis in a research report on Tuesday, September 9th. Finally, Weiss Ratings reissued a “hold (c-)” rating on shares of Zoetis in a research report on Wednesday. Four investment analysts have rated the stock with a Buy rating and five have given a Hold rating to the stock. According to MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $196.71.

Get Our Latest Stock Report on ZTS

About Zoetis

(Free Report)

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.

See Also

Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTSFree Report).

Institutional Ownership by Quarter for Zoetis (NYSE:ZTS)

Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.